

ISFA 2017



The 11th ISFA Congress
17.-20. May 2017

Copenhagen
Denmark

www.isfa2017.dk



TIVOLI
Hotel & Congress Center

WELCOME

On behalf of the organizing Committee, I am very pleased to welcome you to the ISFA 2017 in Copenhagen, as well as the pre-symposium on May 17th. This is the first time this meeting has been held in Denmark, and we are proud to host this event in the beautiful Tivoli Congress Center.

The preparation of the Congress was difficult due to changing EU rules regarding cooperation with industrial partners, and limitations regarding how they can sponsor medical conferences and delegates. More than 300 attendees from all over the world are joining us in Copenhagen today. ISFA is the only International society for Apheresis that is mainly composed of individual members. We would especially like to thank our speakers, all of whom are travelling to Denmark on their own funds.

The field of Apheresis is expanding, as new indications are confirmed in clinical Randomized Control Trials. We are excited to have the most recent studies presented at this conference. Presentations will include the latest Apheresis developments in the fields of transplantation, stem cell production, eclampsia, coagulation disorders, IgE-mediated diseases, small vessel vasculitis and severe dyslipidemias.

Dear All,

A warm welcome to Copenhagen in spring time.

I am delighted that the ISFA Congress 2017 has chosen Copenhagen as its venue. Not least, because we consider our city as a center for the health and medical sciences.

In Copenhagen you will find research, innovation, education, health care and regulatory bodies – all connected and all within reach.

Here, we have several research and education institutions, numerous science parks and a strong life science with a variety of medtech, pharma and biotech companies. No wonder we are considered one of the best country with regards to innovation potential.

This potential originates from a long tradition within the health and medical sciences, a smooth corporation between hospitals, uni-

We have invited clinical researchers as well as specialists in Apheresis to this meeting in the hope that both communities will learn from each other and develop new indications for apheresis as well as new techniques, based on their interactions. In addition, we hope that this Congress will build another bridge between the medical and bioengineering communities in order to refine our tools and techniques.

I hope that the coming four days will provide all attendees with a rich opportunity to exchange the latest results in the field of Therapeutic Apheresis. Enjoy the 11th ISFA Congress and Wonderful Copenhagen, where you are assured of the warmest of welcomes.

Wladimir Szpirt

11th ISFA Congress and ISFA President



*Yoshihiro Endo ISFA President elect and
Wladimir Szpirt ISFA President*

versity and industry as well as a focus on the need for exceptional talent and state of the art infrastructure.

Take the new Mærsk Tower as an example. Placed within the Copenhagen Science City Area it has 15 floor of ultra-modern facilities and over 42,000 square meters of space for research, education and dissemination.

This is one of our ways to be of use to the world which is the only way to be happy, as famous author Hans Christian Andersen once said.

Enjoy Your stay,



Ulla Wewer

Dean of Health and Medical
Sciences
University of Copenhagen



Congress Venue:

Tivoli Congress Center
Arni Magnussons Gade 2
1577 Copenhagen V
Phone +45 45 99 00 00

**ORGANIZING
COMMITTEE**

Lisbet Brandt
Anne Marie Boeskov
Peter Clausen
Bo Feldt-Rasmussen
Ditte Hansen
Mads Hornum
Vibeke Kristensen
Vibeke Rømming
Fin Stolze Larsen
Wladimir Szpirt

**SCIENTIFIC
COMMITTEE**

Japan
Tadao Akizawa
Yoshihiro Endo
Yutaka Eguchi
Motoshi Hattori
Shigau Ikeda
Hidenori Matsuo
Michio Mineshima
Shigeto Oda
Koji Sawada
Mariko Shiba
Tohru Tani
Yasunori Ueda
Ken Yamaji

Europe
Bernd Hohenstein
Wolfgang Ramlow
Wladimir Szpirt
Kurt Defler
Witt Volker
Bernd Stegmayr
Jan Kielstein
Steffen Mitzner

USA
Andre Kaplan
Paul Malchesky
Patrick Moriarty
Yosi Schwartz
Robert Weinstein

PROGRAM

| WEDNESDAY 17 MAY 2017 | | | |
|-----------------------|---------------------------------|---|---------|
| | CARSTENSEN | LUMBYE | PJERROT |
| 8.00 | | | |
| 9.00 | | | |
| 10.00 | | | |
| 11.00 | | | |
| 12.00 | | | |
| 13.00 | | FRESENIUS KABI Pre-Congress Symposium <i>Volker WITT (chair)</i> Instrumentation overview - Dr. Leitner, Austria Implementation of a new apheresis platform - Matthew Schooner Therapeutic apheresis in pediatric patients - Dr. V. Witt, Austria | |
| 14.00 | | | |
| 15.00 | | | |
| 16.00 | | | |
| 17.00 | | | |
| 18.00 | Reception City Hall 18.00-19.30 | | |

THURSDAY 18 MAY 2017

| | CARSTENSEN | LUMBYE | PJERROT |
|-------|---|---|---|
| 8.00 | Opening ceremony-dekan of University 08.15-08.30 | | |
| 8.30 | KIDNEY TRANSPLANTATION I <i>Chairmen: Georg Boehming and Mads Homum</i> Søren Schwartz Sørensen (Denmark): ABO-incompatible kidney transplantation Copenhagen experience 08.30-09.00 | CARDIOVASCULAR DISEASES I <i>Chairmen: Ulrich Julius and Wolfgang Ramlow</i> Peter Lansberg (Netherlands): LDL-C and HDL-C = black and white for the cardiovascular risk - a critical overview 08.30-09.00 | PEDIATRIC APHERESIS I <i>Chairmen: Joseph Schwartz and Motoshi Hattori</i> Alina Casian (UK): Pediatric Apheresis in nephrology 08.30-08.55 |
| 9.00 | Georg Boehming (Austria): The role of immunoadsorption before and after kidney TX - 20 yrs Vienna experience 09.00-09.30 | Pia Kamstrup (Denmark): Lp(a) as cardiovascular risk factor - conclusions from the Copenhagen Cohort study 09.00-09.30 | Motoshi Hattori (Japan): Apheresis in the pediatric nephrology Japanese experience 08.55-09.20 |
| 9.30 | P. Malvezzi (France): Effect of double-filtration plasmapheresis for antibody-mediated rejection regarding coagulation parameters and thrombin generation 09.30-09.45 | P. Barton Duell (USA): The link between Lp(a) and PCSK9 under apheresis conditions 09.30-10.00 | Rachel Pawson (UK): mobilization protocols & success of engraftment in pediatrics 09.20-09.45 Khaled El-Ghariani (UK): Stem cell collections in pediatrics 09.45-10.05 |
| 10.00 | Coffee | | |
| 10.30 | IMMUNE APHERESIS I <i>Chairmen: Hiroaki Ogata and Volker Schettler</i> Hiroaki Ogata (Japan): New application for therapeutic apheresis in nephrology 10.30-11.00 | CARDIOVASCULAR DISEASES II <i>Chairmen: Mariko Harada-Shiba and Kurt Defler</i> Anja Vogt (Germany): The Odyssey ESCAPE trial and it's consequences for the application of LDL-apheresis 10.30-11.00 | APHERESIS SYMPOSIUM ON: ASFA MEETS ISFA <i>Chairmen: Bruce Sachais and Yoshi Endo</i> B. Weinstein (USA): Evidence and decision making in Apheresis Medicine 10.30-10.50 |
| 11.00 | Dobri Kiprof (USA): Autoimmunity and Immunosenescence - is there a role for TPE? 11.00-11.30 | Mariko Harada-Shiba (Japan): Long-term outcome of apheresis treatment in patients with severe cardiovascular disease resulting from hypercholesterolemia 11.00-11.30 | Bruce Sachais (USA) President of ASFA :TPE research ASFA perspective 10.50-11.10 |

THURSDAY 18 MAY 2017

| | CARSTENSEN | LUMBYE | PJERROT |
|-------|--|---|--|
| 11.30 | <p>Heinrich Prophet (Germany): Long-term surveillance of atherosclerosis by carotid ultrasound in a single apheresis center cohort 11.30-12.00</p> | <p>Patrick Moriarty (USA): Novel Drug Therapies for the Treatment of Hypercholesterolemia 11.30-12.00</p> | <p>Qualification In Apheresis (QIA) – A New Credential for Apheresis Practitioners</p> <p>Christina Anderson, BSN, RN, HP (ASCP)QIA – What is it and who is it for? 11.10-11.30</p> <p>Christine Fernandez RN MSN/Ed OCNQIA – How do I prepare for the exam? 11.30-11.50</p> |
| 12.00 | ISFA Board Meeting | | <p>LUNCH SYMPOSIUM TERUMO BCT Clinical considerations of plasma exchange</p> <p>Centrifugal Therapeutic Plasma Exchange (TPE) vs. membrane TPE – Jan Kielstein</p> <p>Anticoagulant management in therapeutic Plasma Exchange Miguel Lozano</p> <p>Vascular Access: multiple options and single needle – Paolo Malvezzi</p> |
| 13.00 | <p>IMMUNE APHERESIS II - AUTOIMMUNE VASCULITIDIES</p> <p><i>Chairmen: Wladimir Szpirt and David Jayne</i></p> <p>Wladimir Szpirt (Denmark) TPE in Vasculitis and Low dose Cyclophosphamide 13.00-13.20</p> | <p>CARDIOVASCULAR DISEASES III</p> <p><i>Chairmen Patrick Moriarty and Mariko Hirada-Shiba</i></p> <p>Sotirios Tsimikas (USA): Modern anti-sense technology to lower high Lp(a) - current status and next steps 13.00-13.30</p> | <p>SYMPOSIUM ON: Registries B. Stegmayr (Sweden)</p> <p><i>Chairmen: Bernd Stegmayr and Robert Weinstein</i></p> <p>Christian Peter (Germany): From Cardiometabolic to dyslipidemia register 13.00-13.20.</p> |
| 13.30 | <p>Alina Casian (UK) - Lung haemorrhage and TPE 13.20-13.40</p> <p>David Jayne - (UK) : Update on PEXIVAS 6 years gone 6 months to go 13.40-14.00</p> | <p>Ulrich Julius (Germany): Perspectives of lipoprotein apheresis in patients with high lipoprotein(a) 13.30-14.00</p> | <p>Bernd Stegmayr (Sweden): Update on the WAA apheresis registry 13.20-13.40</p> <p>Volker Schettler (Germany): The German Lipoprotein Apheresis Register - Current status and future developments 13.40-14.00</p> |

THURSDAY 18 MAY 2017

| | CARSTENSEN | LUMBYE | PJERROT |
|-------|---|--|--|
| 14.00 | Shouchi Fujimoto (Japan): Utility of therapeutic apheresis in ANCA vasculitis - Japanese experience 14.00-14.20 | Wolfgang Ramlow (Germany): Still a future for lipoprotein apheresis despite powerful novel drug developments? 14.00-14.30 | SYMPOSIUM ON: Apheresis Regulations and Reimbursement Sandra Flora Siami (USA) Therapeutic Apheresis Regulation and Reimbursement in the United States 14.00-14.30 |
| 14.30 | Zdenka Hrustova (Czech rep.) Plasma exchange in ANCA-associated vasculitis - single-centre experience. 14.20-14.45 Zdenka Hrustova (Czech rep.) - Czech Vasculitis Registry 14.45-15.00 | Bernd Hohenstein (Germany): the MultiSELCT Lp(a) trial protocol and current status 14.30-15.00 | Uwe-H. Wallstab (Germany): Europe - Clinical Evaluation of Medical Devices: 14.30-15.00 |
| 15.00 | Coffee | | |
| 15.30 | OTHERS - NEW INDICATIONS <i>Chairmen: Bruce Sachais and Heinrich Prophet</i> Carmen Scheibenbogen (Germany): Chronic fatigue syndrome - is there a rational for apheresis treatment? 15.30-16.00 | APHERESIS IN CRITICAL CARE I <i>Chairmen: Steffen Mitzner and Fin Stoltze Larsen</i> Martin Sauer (Germany): Hemodynamics and liver function - important outcome parameters of extracorporeal therapies, especially in septic patients. 15.30-16.00 | PHOTOPHERESIS <i>Chairmen: Yasunori Ueda and Lionel Rostaing</i> Rachel Pawson (UK) TPE in Myelomatosis/Waldenström 15.30-16.00 |
| 16.00 | R. Weinstein (USA): Emerging indications for therapeutic apheresis (based on recent case reports) 16.00-16.30 | Steffen Mitzner (Germany): Liver support therapies: evidence update 2017 16.00-16.30 | Marietta Nygaard (Denmark) Photopheresis in GvH 16.00-16.25 Manuela Härtel (Germany): Photopheresis in solid organ transplantation 16.25-16.45 |

THURSDAY 18 MAY 2017

| | CARSTENSEN | LUMBYE | PJERROT |
|-------|--|---|--|
| 16.30 | Wolfgang Ries (Germany): CrP adsorption in acute myocardial infarction 16.30-17.00 | Fin Stolze Larsen (Denmark): High Volume TPE in critical hepatic coma 16.30-17.00 | P. Kampmann et al. (Denmark): First line apheresis in acquired hemophilia 16.45 -17.00 |
| 17.00 | | Round table discussion 17.00-17.30 Prescription of Volume in TPE with Jan Kielstein and Wladimir Szpirt + moderator Andre Kaplan | |
| 17.30 | | | |

FRIDAY 19 MAY 2017

| | CARSTENSEN | LUMBYE | PJERROT |
|-------|--|--|---|
| 8.30 | <p>APHERESIS IN CRITICAL CARE - SEPSIS <i>Chairmen: Steffen Mitzner and Shigeto Oda</i> Jan Kielstein (Germany): Apheresis therapy in Sepsis 08.30-08.50</p> | <p><i>Chairmen: Reinhard Klingel and Anja Vogt</i> Mariko Hirada-Shiba (Japan): MTP inhibitor and apheresis therapy in patients with homozygous hypercholesterolemia - experiences from Japan 08.30-08.55</p> | <p>APHERESIS IN COMPLEMENT RELATED CONDITIONS <i>Chairmen: Wladimir Szpirt and Georg Boehmig</i> David Jayne (UK) - Biological agents and TPE - can they coexist in the future? 08.30-09.00</p> |
| 9.00 | <p>Jens Altrichter (Germany): Personalized cell therapy of sepsis - combining cellular diagnostic and extracorporeal cellular therapy 08.50-09.20</p> <p>Yoshihiro Endo (Japan): Apheresis therapy in septic patients - the Japanese perspective 09.20-09.40</p> | <p>Patrick Moriarty: Novel Drug Therapies for the Treatment of Hypercholesterolemia 09.00-09.30</p> | <p>Andreas Kronbichler (Austria) - TPE strategy in Complement mediated diseases - an overview 09.00-09.30</p> |
| 9.30 | <p>Steffen Mitzner(Germany) : Selective apheresis techniques in critical care 09.40-10.00</p> | <p>Ghodrat Siami (USA): Overview on selective lipid apheresis technologies 09.30-10.00</p> | <p>David Jayne (UK) - Clear Trial - Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 09.30-10.00</p> |
| 10.00 | Coffee | | |
| 10.30 | <p>IMMUNE APHERESIS III <i>Chairmen: Hidenori Matsuo and Grit Waitz</i> Anupam Bhattacharjee (UK): Use of plasma exchange in GBS and CIDP - evidence review and proposed mechanism of action of TPE in those diseases 10.30-11.00</p> | <p>CARDIOVASCULAR DISEASES V <i>Chairmen: Wolfgang Ramlow and Patrick Moriarty</i> Tina Z. Khan (UK): Apheresis in unstable angina patients with high Lp(a) - conclusions from a crossover trial 10.30-11.50</p> | <p>SYMPOSIUM ON: APHERESIS IN IMMUNE RELATED CONDITIONS -SLE <i>Chairmen: Alina Casian and Kurt Defler</i> Andreas Kronbichler (Austria) - Extracorporeal treatment strategies in the management of SLE 10.30-11.00</p> |
| 11.00 | <p>Joanne Kitley (UK): Use of plasma exchange in MG and comparison with NMO - evidence review and proposed mechanism of actions of TPE in those diseases. 11.00-11.30</p> | <p>Claudia Stefanutti (Italy): Pleiotropic effects of lipoprotein apheresis 11.50-11.15</p> | <p>Kurt Defler (Austria) - Long term TPE results in nephrological disorders - Vienna experience 11.00-11.30</p> |

FRIDAY 19 MAY 2017

| | CARSTENSEN | LUMBYE | PJERROT |
|-------|--|---|---|
| 11.30 | <p>Bernd Hohenstein (Germany) : Presentation of coming activities of e-ISFA and Vienna Congress 2018. 11.30-11.50</p> | <p>Reinhard Klingel (Germany) : Clinical and molecular characterisation of patients treated by long-term lipoprotein apheresis due to Lp(a)-hypolipoproteinemia according to German national guidelines. 11.15-11.35</p> <p>Ulrich Julius (Germany): Perspectives of lipoprotein apheresis in patients with high lipoprotein(a) 11.35-12.00</p> | <p>Kusaoi M (Japan): Separation of circulating micro RNAs using apheresis in patient with systemic lupus erythematosus 11.30-12.00</p> |
| 12.00 | | | <p>LUNCH SYMPOSIUM FRESENIUS Immunoabsorption in Membranous Nephropathy: Insights & Updates from the Manchester Working Group. Dr. Patrick Hamilton, Manchester, UK Immunoabsorption in Early Dementia – Rationale and First Results in Vascular and Cognitive Outcome. PD Dr. Sönke Langner, Greifswald, Germany Immunoabsorption in Multiple Sclerosis – Current Evidence Level and Outlook. Dr. Johannes Dorst, Ulm, Germany</p> |
| 13.00 | <p>MISCELLANEOUS I <i>Chairmen: Bernd Hohenstein and Ken Yamaji</i> Petar Kes (Croatia): Treatment of hypertriglyceridemia in a pregnant woman 13.00-13.30</p> | <p>HUS-TTP/ PRECLAMPSIA <i>Chairmen: Jan Kielstein and Marie Scully</i> Henning Haggmann (Germany): The role of apheresis therapy in pre-eclampsia - rationale and first clinical results 13.00-13.25</p> | <p>ORAL COMMUNICATIONS <i>Chairmen: Stefan Mitzner and Wolfgang Ramlow</i> Frederick Sanderson (France): Evaluation of a new automated red cell exchange procedure in routine use 13.00-13.20</p> |

FRIDAY 19 MAY 2017

| | CARSTENSEN | LUMBYE | PJERROT |
|-------|---|--|--|
| 13.30 | Isaac Eliaz (USA) -The role of Galectin-3 removal in inflammatory and fibrotic diseases. 13.30-14.00 | Marie Scully (UK) TTP and atypical HUS in Pregnancy 13.25-13.50 | Jens Altrichter (Germany): Terminal sterilization of extracorporeal devices 13.20-14.00 |
| 14.00 | Grit Waitz (Germany): Adsorptive cytapheeresis in ulcerative colitis - Current practice in Europe 14.00-14.30 | Diana Karpman (Sverige) - Microvesicles in hemolytic uremic syndrome 13.50-14.15 Marie Scully (UK): Apheresis and aquired TTP - Titan study with Caplacizumab 14.15-14.35 | Yuki Hattori (Japan): Recurrent Sweet syndrome successfully treated with granulocyte and monocyte apheresis 14.00-14.20 |
| 14.30 | Lionel Rostaing (France) -Effect of double-filtration plasmapheresis for antibody-mediated rejection regarding coagulation parameters and thrombin generation 14.30-15.00 | Claudia Stefanutti (Italy): TPE in Pregnancy: Differential Indications with positive maternal and fetal outcome. 14.35-15.00 | Jon Waarst Gregersen (Denmark): Early plasma exchange improves outcome in PR3-ANCA vasculitis - A three year follow-up study 14.20-14.40 Tomoharu Shimizu (Japan): The prognosis and indication of blood purification in a patient with colorectal perforation according to new definition of Sepsis-3 14.40-15.00 |
| 15.00 | Coffee | | |
| 15.30 | MISCELLANEOUS III <i>Chairmen: Robert Weinstein and Shigau Ikeda</i> Yutaka Eguchi (Japan): Apheresis in critical care using plasma diafiltration 15.30-16.00 | MISCELLANEOUS IV <i>Chairmen: Wolfgang Ramelow and Dusit Lumlertgul</i> Peter Klein-Weigel (Germany): Immunoabsorption in thrombangitis obliterans 15.30-16.00 | ORAL COMMUNICATIONS <i>Chairmen: Joseph Schwartz and Volker Witt</i> Volker Witt (Austria): Indications and technical challenges for Apheresis in children 15.30-16.00 Anna Maria Pugliese et al. (Argentina): Overview of therapeutic plasma exchange in pediatrics. Experience in a third level hospital between 1994-2016 16.00-16.20 |

FRIDAY 19 MAY 2017

| | CARSTENSEN | LUMBYE | PJERROT |
|-------|--|--|---|
| 16.00 | Robert Weinstein (USA): Apheresis in tandem with hemodialysis: is supplemental calcium always necessary? 16.00-16.30 | Ken Yamaji (Japan): Apheresis treatment in collagen disease - the Japanese perspective 16.00-16.30 | Wolfgang Ries (Germany) "CrP adsorption in pancreatitis" 16.20-16.40 |
| 16.30 | Round table discussion 16.30-17.00 Tandem Apheresis PRO Rostaing and AGAINST Szpirt + moderator Weinstein | Dusit Lumlertgul (Thailand): Hemorheopheresis for diabetic foot syndrome no response 16.30-17.00 | Elie Moubarak (Lebanon): Familial hypercholesterolemia: efficiency and safety of the treatment - Lebanese experience 16.40-17.00 |
| 17.00 | A-HUS SYMPOSIUM SUPPORTED BY UNRESTRICTED GRANT FROM ALEXION - Moderator B. Hohenstein Seppo Meri pathogenesis of aHUS Fadi Fakhouri - a-HUS Treatment challenges T. Sakari Jokiranta -a-HUS and complement | | |
| 18.00 | ISFA General Assembly | | |
| 19.00 | Congress banquet - boat canal trip 30 minutes and dinner at 20.00 Langelinie Pavillonon | | |

SATURDAY 20 MAY 2017

| | CARSTENSEN | LUMBYE |
|-------|--|--|
| 9.00 | MISCELLANEOUS V <i>Chairmen: Wolfgang Ramlow and Georg Boehming</i> Toshihide Naganuma (Japan): Selective apheresis in ABO-incompatible kidney transplantation 09.00-09.20 | TECHNICAL ISSUES <i>Chairmen: Michio Mineshima and Paul Malchesky</i> Paul Malchesky (USA): Membrane Plasma Separation and Therapeutic Plasma Filtration 09.00-09.20 |
| | Jakob Gubensek (Slovenia): A decade of experience with the treatment of antibody-mediated rejection after kidney transplantation 09.20-09-40 | Michio Mineshima (Japan): Membrane technology for apheresis 09.20-09.40 |
| 9.30 | | Marie Scully (UK): A single-center prospective study on the safety of TPE using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy. 09.40-10.00 |
| 10.00 | Coffee | |
| 11.00 | REGULATORY ISSUES + GUIDELINES <i>Chairmen: Bob Weinstein and Joseph Schwartz</i> Shepard Bentley (USA): Current regulatory aspects for apheresis systems from FDA 11.00-11.20 | APHERESIS HISTORY <i>Chairmen: Ulrich Julius and Andre Kaplan</i> Horst Klinkmann (Germany): The Changing Pattern (since 1978) of Therapeutic Apheresis - a historical reflection. 11.00-11.20 |
| 11.30 | Josef Schwartz (USA): Development and implementation of guidelines - what to be learned from ASFA? 11.20-11.40 | Paul Malchesky (USA): The Early Cleveland Clinic Experiences in Therapeutic Apheresis 11.20-11.40 |
| | Uwe-H. Wallstab (Germany): New European Medical Device Regulation - Significant changes in the device approval process 11.40-12.00 | Andre Kaplan (USA) TPE in the 70ties and 80ties - USA experience. 11.40-12.00 |
| 12.00 | Lunch | |
| 13.00 | ISFA CLOSING SESSION <i>Chairmen: Wladimir Szpirt and Yoshiro Endo</i> Bernd Hohenstein (Germany): Future perspectives of immune apheresis 13.00-13.30 Closing ceremony See You in Kyoto 2019. | |